Annovis Bio will target Alzheimer’s disease and Parkinson’s disease with two Phase III trials in early 2022, CEO Maria Maccecchini says. The Pennsylvania-based biotech has requested a meeting with the FDA for its Parkinson’s trial, and it intends to file a similar request for Alzheimer’s within the next two weeks, Maccecchini says, adding that a […]

David Liu is best known as one of the pioneers of the experimental science of editing people’s genes. Liu’s laboratory at the Broad Institute of MIT and Harvard was the birthplace of two new types of gene-editing called base and prime editing, that swap out segments of the DNA strand without cutting into it. He and other […]

Glympse Bio has developed a liquid biopsy with the potential to diagnose and monitor non-alcoholic steatohepatitis (NASH) with significantly higher accuracy and less invasiveness than needle biopsies, according to a late-breaking presentation at the American Association for the Study of Liver Disease (AASLD) annual The Liver Meeting, held virtually November 12-15. This liquid biopsy uses a panel […]